NEWS HIGHLIGHTSMedia Articles Related to Antabuse (Disulfiram)
Alkermes Initiates Phase 2 Clinical Study Of ALKS 33 For The Treatment Of Alcohol Dependence
Source: Alcohol / Addiction / Illegal Drugs News From Medical News Today [2009.11.19]
Alkermes, Inc. (NASDAQ: ALKS) announced the initiation of a phase 2 clinical study of ALKS 33, an investigational oral opioid modulator for the potential treatment of alcohol dependence and other central nervous system disorders. The study will assess the safety and efficacy of multiple doses of ALKS 33 in patients with alcohol dependence and is designed to further define the clinical profile of ALKS 33.
Published Studies Related to Antabuse (Disulfiram)
A double blind, placebo-controlled trial that combines disulfiram and naltrexone for treating co-occurring cocaine and alcohol dependence. [2008.05]
BACKGROUND: This is a double blind, placebo-controlled trial that evaluated the efficacy of disulfiram, naltrexone and their combination in patients with co-occurring cocaine and alcohol dependence... CONCLUSION: There was an association between disulfiram treatment and abstinence from cocaine and alcohol. More patients taking the disulfiram-naltrexone combination achieved 3 consecutive weeks of abstinence in treatment than placebo-treated patients.
A randomized, multicentre, open-label, comparative trial of disulfiram, naltrexone and acamprosate in the treatment of alcohol dependence. [2008.01]
CONCLUSIONS: Patients allocated to ACA, NTX and DIS combined with brief manual-based cognitive behavioural intervention significantly reduce their alcohol consumption and report improved QL. Supervised DIS appeared superior, especially during the continuous medication period, to NTX and ACA.
Naltrexone and disulfiram in patients with alcohol dependence and current depression. [2007.04]
CONCLUSIONS: The results suggest that disulfiram and naltrexone are safe pharmacotherapeutic agents for dually diagnosed individuals with depression for the treatment of alcohol use disorders.
Disulfiram effects on responses to intravenous cocaine administration. [2007.03.16]
Disulfiram has been studied as a treatment for cocaine dependence. We report results of a randomized, double-blind, placebo-controlled, within-subject study to examine the interaction of disulfiram with intravenous cocaine... CONCLUSIONS: Disulfiram decreased cocaine clearance without toxicity. Cocaine 'high' and 'rush' were diminished. Disulfiram may be a promising pharmacotherapy in selected cocaine dependent individuals.
Short-term efficacy of Disulfiram or Naltrexone in reducing positive urinalysis for both cocaine and cocaethylene in cocaine abusers: A pilot study. [2007.02]
Cocaine abusers frequently report taking the drug in association with alcohol. This combined intake leads to the synthesis of cocaethylene, an active metabolite with effects similar to those of cocaine, but more prolonged...
Clinical Trials Related to Antabuse (Disulfiram)
Disulfiram Interactions With HIV Medications: Clinical Implications [Recruiting]
The purpose of this study is to determine whether disulfiram might be a safe and effective
treatment for cocaine and/or alcohol dependence in patients with HIV disease. This research
is designed to characterize the presence or absence of significant drug interactions between
disulfiram and HIV medications using standard clinical pharmacology techniques as well as
monitor any side effects that might occur when these medications are administered together.
Phase I Study of Disulfiram and Copper Gluconate for the Treatment of Refractory Solid Tumors Involving the Liver [Recruiting]
OBJECTIVES:
Primary Objectives
• Determine the safety and toxicity profile of co-administration of disulfiram and copper
gluconate for the treatment of refractory malignancies that have metastasized to the liver.
Secondary Objectives
- Determine if disulfiram and copper gluconate induce measurable responses for the
treatment of hepatic metastases from solid tumors.
- Qualitative assessment of the induction of S-glutathionylation in proteins of
circulating leukocytes in patients treated with disulfiram and copper gluconate.
Antabuse in Severe Alcoholism: an Open Controlled Study [Recruiting]
Newly detoxified alcoholics (N=60) are randomised to either antabuse (disulfiram) treatment
or the control group for a total of 6 months. All patients will receive cognitive behavioural
treatment in groups. The hypothesis to be tested is that more of the patients who receive
antabuse (disulfiram) will be alcohol free during the 6 months treatment period compared to
the control group. The trial is open.
Pharmacogenetics of Disulfiram for Cocaine [Recruiting]
Previous research has shown that disulfiram, a medication sometimes used for treating
alcoholism, discourages cocaine use among cocaine addicts who are undergoing methadone
treatment. By blocking the enzyme dopamine beta hydroxylase (DBH), disulfiram increases
levels of dopamine and produces an unpleasant sense of hyperstimulation and discomfort in
cocaine users. This study will evaluate the effectiveness of disulfiram in preventing drug
relapse among cocaine and opiate addicts with varying inherited levels of DBH.
Evaluation of Disulfiram Plus Arsenic Trioxide In Patients With Metastatic Melanoma and at Least One Prior Systemic Therapy [Recruiting]
Patients with metastatic melanoma (stage IV), who have progressed after one or more courses
of systemic therapy, are recruited to receive Disulfiram plus Arsenic Trioxide. The response
rate and toxicity will be evaluated.
PURPOSE:
The purpose of this research study is to find out how well patients respond and how long
their responses last when treated with Disulfiram (DSF) and arsenic trioxide, what side
effects are caused by DSF and arsenic trioxide, and how often they occur.
Twenty one subjects will be selected to take part of this study. Treatment will be
administered in cycles of 12 weeks and the number of cycles a subject participates in will
vary based on several factors. Subjects will receive pills orally, two times a day, and
continuous bolus infusion over 2-4 hours, daily, Monday-Friday for two weeks followed by a
two week rest period. Routine laboratory tests (including blood and urine) and x rays will
be done during therapy to check the subject's body's response to treatments.
|
